FDA to Review 14 Peptides for Compounding as Kennedy Pushes Easier U.S. Access
Updated
Updated · Livescience.com · Jul 4
FDA to Review 14 Peptides for Compounding as Kennedy Pushes Easier U.S. Access
3 articles · Updated · Livescience.com · Jul 4
Summary
July plans released this week show the FDA will ask outside advisers whether U.S. pharmacies should be allowed to compound peptides including BPC-157, TB-500 and KPV.
Kennedy’s February proposal to legalize compounding of 14 peptides helped trigger the review, potentially easing access to drugs now often bought through overseas or legally murky online markets.
2023 FDA restrictions had barred compounding of several peptides, including BPC-157, GHK-Cu, KPV and ipamorelin, citing significant safety risks.
Human evidence remains sparse: a recent review found only 3 small pilot studies on BPC-157, while experts say dosing, purity and combined-use risks are poorly understood.
Broader availability could accelerate a wellness trend already fueled by influencers, bodybuilding circles and online communities such as r/peptides, which draws more than 70,000 weekly visitors.
If the FDA approves peptides, can it prevent a health crisis without long-term safety data?
Are wellness seekers unknowingly funding former fentanyl suppliers through the peptide gray market?
2026 FDA Peptide Hearings: Regulatory Reversals, Political Pressure, and the Fight for Evidence-Based Access
Overview
The FDA will hold a key Pharmacy Compounding Advisory Committee (PCAC) meeting on July 23-24, 2026, to review clinical evidence for several important peptides. After this review, the committee will decide whether to recommend adding these peptides to the FDA's 503A Bulk Drug Substances List. If included, pharmacies could legally compound these substances, which may increase their availability for certain treatments. This meeting follows the FDA's recent removal of 12 peptides from a restricted category, setting the stage for possible expanded access. The outcome could significantly impact how patients and pharmacies use these peptides in the future.